Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P060005/S027

IMMULITE Systems Free PSA

Siemens Medical Solutions Diagnostics Limited · Decision date Sep 22, 2026

MEDTECHLEDGER EXPLANATIONP060005/S027

What did the FDA decide?

The FDA recorded a 30-Day Notice decision, OK30, dated 2026-09-22 for P060005/S027, a supplement to the IMMULITE Systems Free PSA application held by Siemens Medical Solutions Diagnostics Limited. The supplement type is a 30-Day Notice and the recorded reason is a process change affecting a manufacturer, sterilizer, packager or supplier. The stated scope is to move manufacturing of a critical component within the same facility.

The underlying device category is a free prostate specific antigen (noncomplexed) test intended to distinguish prostate cancer from benign conditions, classified under Immunology with product code MTG. This record covers only the manufacturing-location change described; it is not a new approval of the whole system, and the source does not identify the component, the facility, or any performance data. Whether the change affects analytical performance or labeling remains unknown from this record.

FDA approval order statement

to move manufacturing of a critical component within the same facility
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Immunology
Decision date
Sep 22, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P060005/S027
Regulatory pathway
PMA supplement
Product code
MTG
Decision code
OK30
Decision date
Sep 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Test, prostate specific antigen, free, (noncomplexed) to distinguish prostate cancer from benign conditions.

Product code
MTG
FDA device class
3

For the original device and its historical approval scope, see PMA P060005. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P060005 · Original PMA

    IMMULITE / IMMULITE 1000 AND IMMULITE 2000 FREE PSA ASSAYS

  2. P060005/S022 · Related supplement

    IMMULITE 2000 Systems Free Prostate-Specific Antigen (Free PSA)

  3. P060005/S026 · Related supplement

    IMMULITE Systems Free PSA

  4. P060005/S027 received

    Application receipt date recorded by FDA.

  5. P060005/S027 · FDA decision

    30-Day Notice

Timeline entries are records held by MedtechLedger for P060005. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P060005

Explore the linked device profile

Other records with product code MTG

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Siemens Medical Solutions Diagnostics Limited

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Glyn Rhonwy Llanberis, Caernarfon, Gwynedd Ll55, 4EL

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records